Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- QD +5.2%, ERJ +4.5%, MNTX +3.1%
Other news:
- NVEI +29% (responds to recent press reports speculating as to a potential going-private transaction)
- GOEV +13.4% (announced that the U.S. Department of Commerce has approved its Oklahoma City facility as a Foreign Trade Zone)
- VERI +13.4% (to delay 10-K filing)
- HCP +10% (report it has been considering options including a sale, according to Bloomberg)
- FENC +6.2% (Fennec Pharmaceuticals and Norgine enter into exclusive licensing agreement to commercialize PEDMARQSI in Europe, Australia, and New Zealand)
- LVO +4.3% (provides update for March)
- WEST +3.9% (entered into Equity Distribution Agreement not to exceed 5 mln shares of Common Stock)
- FF +3.8% (provides update on $2.50 per share special cash dividend)
- CSTL +3.4% (New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older)
- TSLA +3.2% (Elon Musk says Model Y price will rise by $1000 in a few weeks)
- BEP +3% (files mixed securities shelf offering)
- PHVS +3% (announces phase 3 clinical study design for recently initiated RAPIDe-3 Study, and presents quality-of-life improvement and caregiver behavior data at Two Recent HAE Congresses)
- KALV +2.8% (presents real-world data on burden of treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas)
- OPTN +2.1% (following trading halt on Friday)
- VVI +2% (files mixed shelf securities offering)
- AVXL +2% (announces that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX3-71 for the treatment of schizophrenia has been screened ahead of schedule)
- DWAC +1.3% (entered into an amendment to the Warrant Agreement in connection with the Business Combination, on March 15)
- PBR +1.2% (clarifies pieces of news in the media)
- HMC +1.2% (sign MOU with Nissan to collaborate on Evs)